Keywords: Sanofi, Regeneron Pharma, Hypercholesterolemia, SAR236553, REGN72, Patient enrollment, Ph III

Sanofi and Regeneron recruiting patients for cardiovascular outcomes trial with antibody to PCSK9 for hypercholesterolemia

Article | 05 November 2012

Print This

French drug major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) say that the ODYSSEY OUTCOMES trial, a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in